Papers
1
Total Citations
1
H-Index
1
About
Fangdong Zhao is a leading surgical oncologist whose research focuses on advancing the treatment of esophageal squamous cell carcinoma (ESCC) through the integration of immunotherapy and robotic surgery. His major contributions lie in evaluating the safety and efficacy of neoadjuvant chemoimmunotherapy (NCI) followed by robot-assisted minimally invasive esophagectomy (RAMIE). In his pivotal 2024 study, Zhao demonstrated that NCI followed by RAMIE has no adverse effect on short-term surgical outcomes compared to surgery alone, providing critical evidence that this combined approach is both feasible and safe for patients with locally advanced ESCC. This work addresses a key clinical question, helping to validate the use of immunotherapy before robotic resection. While his most-cited paper currently holds 1 citation, its recent publication signals growing interest in this emerging field. Zhao’s research is at the forefront of esophageal cancer surgery, bridging the gap between cutting-edge immunotherapy and precision robotic techniques, and his findings are poised to influence future clinical guidelines and treatment protocols.
Research Focus
Key Achievements
Top Papers
- 1